Status:
COMPLETED
Surveillance Study of NovoRapid® for New Drug Re-examination
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
Brief Summary
This study is conducted in Asia. The aim of this study is to observe the safety and efficacy of insulin aspart (NovoRapid®) administered via vial and three different devices.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Subjects with diabetes mellitus (type 1, type 2, or gestational) prescribed with insulin aspart (NovoRapid®)
Exclusion
Key Trial Info
Start Date :
January 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
1239 Patients enrolled
Trial Details
Trial ID
NCT01490112
Start Date
January 1 2005
End Date
June 1 2006
Last Update
October 28 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Seoul, South Korea, 137-920